文献速递骨质疏松与代谢性骨病

加拿大安大略省20年口服双膦酸盐起始治疗的时间趋势反映药物政策与医疗服务变化

Time trends in oral bisphosphonate initiation in Ontario, Canada over 20 years reflect drug policy and healthcare delivery changes.
PubMed 文献 · Osteoporos Int · 2019-07-17

研究利用加拿大安大略省医疗行政数据,纳入1996年4月至2016年3月(1996至2015财年)启动口服双膦酸盐治疗的社区居住老年人(≥66岁)共560,817例(81%为女性),按财年和性别总结药物类型与患者特征。结果显示,1996至2005年多数患者起始环依替膦酸,之后每周方案占主导;2008年利塞膦酸成为主要口服双膦酸盐(46%利塞膦酸、43%阿仑膦酸、11%依替膦酸);2015年71%起始利塞膦酸、28%起始阿仑膦酸、不足2%起始依替膦酸。患者特征随时间变化,男性比例从9%升至28%,糖尿病、他汀使用增加,苯二氮䓬类和雌激素替代治疗减少;作者认为设计骨质疏松药物效应研究时必须考虑这些时间趋势。

要点

  • 1996至2005年多数患者起始环依替膦酸,之后每周方案成为主导。
  • 2008年利塞膦酸成为主要口服双膦酸盐(46%),2015年升至71%。
  • 男性起始治疗比例从9%升至28%,他汀使用增加而苯二氮䓬类减少。

核心结论

  • 启动口服双膦酸盐治疗的患者特征随时间变化,设计骨质疏松药物效应研究时必须考虑这些时间趋势。

研究设计与样本

  • 基于加拿大安大略省医疗行政数据的队列研究,纳入1996年4月至2016年3月(1996至2015财年)启动口服双膦酸盐治疗的社区居住老年人(≥66岁),排除可能影响双膦酸盐处方的非骨质疏松疾病患者,共560,817例(81%为女性)。

主要发现

  • 1996至2005年多数患者起始环依替膦酸,之后每周方案占主导。
  • 2008年利塞膦酸成为主要口服双膦酸盐(46%利塞膦酸、43%阿仑膦酸、11%依替膦酸),月剂型和缓释利塞膦酸上市后其使用增加。
  • 2015年71%患者起始利塞膦酸、28%起始阿仑膦酸、不足2%起始依替膦酸。
  • 随时间推移,男性起始治疗比例从9%升至28%,女性糖尿病患者从10%升至17%,男性糖尿病患者从14%升至22%。
  • 苯二氮䓬类使用女性从22%降至13%、男性从20%降至10%;雌激素替代治疗从1996至2002年的12%降至2008年后的3%;他汀使用女性从15%升至39%、男性从14%升至52%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Characteristics of patients starting oral bisphosphonate therapy changed over time, reflecting trends in osteoporosis management (e.g., new drugs to market), and general healthcare delivery (e.g., benzodiazepine use declined, statin use increased). When designing studies that examine osteoporosis drug effects, potential time-related biases must be considered. INTRODUCTION: To describe the type of oral bisphosphonate initiated and characteristics of patients starting oral bisphosphonate therapy over time. METHODS: We identified community-dwelling older adults (ages ≥ 66 years) initiating oral bisphosphonate therapy from April 1996 to March 2016 (1996 to 2015 fiscal years) using healthcare administrative data in Ontario. Patients with conditions other than osteoporosis that may impact bisphosphonate prescribing were excluded. The bisphosphonate initiated and patient characteristics were summarized by fiscal year and stratified by sex. RESULTS: We identified 560,817 eligible patients (81% women). Most patients initiated cyclical etidronate from 1996 until 2005, and then weekly regimens became dominant. In 2008, risedronate became the main oral bisphosphonate (46% risedronate, 43% alendronate, 11% etidronate); with its use increasing after availability of monthly and delayed-release risedronate formulations. In 2015, 71% of patients started risedronate, 28% started alendronate, and less than 2% started etidronate. Characteristics of patients changed over time, reflecting changes in osteoporosis management and general healthcare delivery. Over time, a larger proportion of men (9% to 28%) and patients with diabetes (women 10% to 17%, men 14% to 22%) initiated therapy; benzodiazepine (women 22% to 13%, men 20% to 10%) and estrogen-based hormone replacement therapy (12% to 15% of women 1996-2002 to 3% since 2008) decreased, while statin use increased (women 15% to 39%, men 14% to 52%). CONCLUSIONS: The characteristics of patients starting oral bisphosphonate therapy have changed over time. Consideration must be given to these time trends when designing studies that examine osteoporosis drug effects.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Hayes KN, Ban JK, Athanasiadis G, et al. Time trends in oral bisphosphonate initiation in Ontario, Canada over 20 years reflect drug policy and healthcare delivery changes. Osteoporos Int. 2019. PMID: 31317249. doi:10.1007/s00198-019-05061-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。